<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60215">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01678235</url>
  </required_header>
  <id_info>
    <org_study_id>Glulisine_Aspart</org_study_id>
    <nct_id>NCT01678235</nct_id>
  </id_info>
  <brief_title>Insulin Glulisine and Aspart in Postprandial Glycemic Control After High-GI Meal in Children With Type 1 Diabetes Mellitus</brief_title>
  <official_title>The Impact Of Insulin Glulisine In Comparison With Aspart On Postprandial Glycemia After The High-Glycemic Index Meal In Children With Type 1 Diabetes - Cross-Over Double-Blind, Randomized Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Warsaw</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Warsaw</source>
  <oversight_info>
    <authority>Poland: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine whether insulin glulisine is more effective in
      postprandial glycemic control than insulin aspart after the H-GI meal in children with type
      1 diabetes (T1DM) treated with insulin pump (CSII).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Some studies have suggested that insulin glulisine (GLU) has a slightly faster onset of
      action compared with insulin aspart (ASP). Meals of high glycemic index (H-GI) have distinct
      effect on postprandial glycaemia (PPG).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">September 2012</completion_date>
  <primary_completion_date type="Anticipated">September 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Postprandial glycemia</measure>
    <time_frame>baseline, 30, 60, 90, 120 and 180 minutes after the breakfast</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia episodes</measure>
    <time_frame>3-h study period</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Hypoglycemia was defined as a PG concentration below 60 mg/dl with or without symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose Area Under the Curve (AUC)</measure>
    <time_frame>3-h study period</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>based on continuous glucose monitoring system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean amplitude of glycemic excursion (MAGE)</measure>
    <time_frame>3-h study period</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between the maximum and baseline glycemia</measure>
    <time_frame>3-h study period</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Questionnaire: Glycemic Index Knowledge</measure>
    <time_frame>each subject was asked to fullfill the questionnaire before entering the study (day one)</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>GLU_ASP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-breakfast insulin was given as a standard bolus 15 minutes before the high-glycemic index meal (cornflakes and milk). The carbo-insulin ratio on both study days was identical to the patient's ratio when entering trial.
First day: insulin glulisine
Second day: insulin aspart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASP_GLU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-breakfast insulin was given as a standard bolus 15 minutes before the high-glycemic index meal (cornflakes and milk). The carbo-insulin ratio on both study days was identical to the patient's ratio when entering trial.
First day: insulin aspart
Second day: insulin glulisine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glulisine</intervention_name>
    <arm_group_label>GLU_ASP</arm_group_label>
    <arm_group_label>ASP_GLU</arm_group_label>
    <other_name>Apidra®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin aspart</intervention_name>
    <arm_group_label>GLU_ASP</arm_group_label>
    <arm_group_label>ASP_GLU</arm_group_label>
    <other_name>NovoRapid®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 diabetes mellitus

          -  CSII for at least 3 months

          -  Duration of diabetes &gt; 1 years

          -  Informed consent

        Exclusion Criteria:

          -  Concomitant dietary restrictions (e.g. celiac disease or food allergy)

          -  Diabetes related complications

          -  Baseline hyperglycemia &gt;150 mg/dl

          -  Any disease judged by the investigator to affect the trial
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katarzyna Dżygało, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pediatrics, Medical University of Warsaw, Poland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katarzyna Dżygało, MD</last_name>
    <phone>+48224523284</phone>
    <email>k.dzygalo@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Agnieszka Szypowska, A. Professor</last_name>
    <phone>+48224523284</phone>
    <email>agnieszka.szypowska@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Pediatrics, Medical University of Warsaw, Poland</name>
      <address>
        <city>Warsaw</city>
        <zip>01-184</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Katarzyna Dżygało, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>September 3, 2012</lastchanged_date>
  <firstreceived_date>August 28, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>insulin pump</keyword>
  <keyword>glulisine</keyword>
  <keyword>aspart</keyword>
  <keyword>glycemic index</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin aspart</mesh_term>
    <mesh_term>Insulin glulisine</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
